No definition available.

Name:	crdf_DerivativeFinancialInstrumentsLiabilityRollForward
Namespace Prefix:	crdf_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the estimated fair value of warrant.

+ References

No definition available.

+ Details

Name:	crdf_EstimatedFairValueOfWarrant
Namespace Prefix:	crdf_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of warrants or rights outstanding.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

+ Details

Name:	us-gaap_DerivativeLiabilitiesNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_FairValueInputsQuantitativeInformationAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

+ Details

Name:	us-gaap_UnrealizedGainLossOnDerivatives
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingMeasurementInput
Namespace Prefix:	us-gaap_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_WeightedAverageMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Derivative Financial Instruments - Warrants (Details)	3 Months Ended		6 Months Ended
Derivative Financial Instruments - Warrants (Details)	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) $ / shares	Dec. 31, 2018
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares) \| shares			10,589,482
Balance of warrants outstanding at the end of the period (in shares) \| shares	12,329,435		12,329,435
Balance of derivative financial instruments liability at the beginning of the period			$ 4,127
Change in fair value of derivative financial instruments—warrants during the period recognized as a loss in the condensed statements of operations	$ (44,144)	$ 23,789	(42,037)	$ 14,028
Balance of derivative financial instruments liability at the end of the period	$ 46,164		$ 46,164
Warrants to purchase Common Stock \| Weighted Average
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share) \| $ / shares	$ 5.01
Warrants to purchase Common Stock \| Black Scholes Option Pricing Method
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares) \| shares			64,496
Balance of warrants outstanding at the end of the period (in shares) \| shares	64,496		64,496
Balance of derivative financial instruments liability at the beginning of the period			$ 4,127
Change in fair value of derivative financial instruments—warrants during the period recognized as a loss in the condensed statements of operations			42,037
Balance of derivative financial instruments liability at the end of the period	$ 46,164		$ 46,164
Warrants to purchase Common Stock \| Black Scholes Option Pricing Method \| Minimum
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share) \| $ / shares			$ 1.01	$ 2.50
Warrants to purchase Common Stock \| Black Scholes Option Pricing Method \| Maximum
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share) \| $ / shares			$ 5.01	$ 3.75
Expected warrant term \| Warrants to purchase Common Stock \| Weighted Average
Range of assumptions used to determine the fair value of warrants
Expected warrant term	2 years 7 months 6 days		2 years 7 months 6 days
Expected warrant term \| Warrants to purchase Common Stock \| Black Scholes Option Pricing Method \| Minimum
Range of assumptions used to determine the fair value of warrants
Expected warrant term	2 years 7 months 6 days	3 years 7 months 6 days	2 years 7 months 6 days	3 years 7 months 6 days
Expected warrant term \| Warrants to purchase Common Stock \| Black Scholes Option Pricing Method \| Maximum
Range of assumptions used to determine the fair value of warrants
Expected warrant term	3 years 1 month 6 days	4 years 1 month 6 days	3 years 1 month 6 days	4 years 1 month 6 days
Risk-free interest rate \| Warrants to purchase Common Stock \| Weighted Average
Range of assumptions used to determine the fair value of warrants
Measurement input	0.0017		0.0017
Risk-free interest rate \| Warrants to purchase Common Stock \| Black Scholes Option Pricing Method \| Minimum
Range of assumptions used to determine the fair value of warrants
Measurement input	0.0017	0.0172	0.0017	0.0172
Risk-free interest rate \| Warrants to purchase Common Stock \| Black Scholes Option Pricing Method \| Maximum
Range of assumptions used to determine the fair value of warrants
Measurement input	0.0162	0.0249	0.0162	0.0249
Expected volatility of Cardiff Oncology common stock \| Warrants to purchase Common Stock \| Weighted Average
Range of assumptions used to determine the fair value of warrants
Measurement input	1.18		1.18
Expected volatility of Cardiff Oncology common stock \| Warrants to purchase Common Stock \| Black Scholes Option Pricing Method \| Minimum
Range of assumptions used to determine the fair value of warrants
Measurement input	1.11	1.02	1.11	1.02
Expected volatility of Cardiff Oncology common stock \| Warrants to purchase Common Stock \| Black Scholes Option Pricing Method \| Maximum
Range of assumptions used to determine the fair value of warrants
Measurement input	1.18	1.06	1.18	1.06
Dividend yield \| Warrants to purchase Common Stock \| Weighted Average
Range of assumptions used to determine the fair value of warrants
Measurement input	0		0
Dividend yield \| Warrants to purchase Common Stock \| Black Scholes Option Pricing Method
Range of assumptions used to determine the fair value of warrants
Measurement input	0		0		0